Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H13NO |
| Molecular Weight | 175.227 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(N)CC1=CC2=C(OC=C2)C=C1
InChI
InChIKey=VKUMKUZDZWHMQU-UHFFFAOYSA-N
InChI=1S/C11H13NO/c1-8(12)6-9-2-3-11-10(7-9)4-5-13-11/h2-5,7-8H,6,12H2,1H3
| Molecular Formula | C11H13NO |
| Molecular Weight | 175.227 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:49:42 UTC 2023
by
admin
on
Sat Dec 16 19:49:42 UTC 2023
|
| Record UNII |
2M3825704H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-5-APB
Created by
admin on Sat Dec 16 19:49:43 UTC 2023 , Edited by admin on Sat Dec 16 19:49:43 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2M3825704H
Created by
admin on Sat Dec 16 19:49:43 UTC 2023 , Edited by admin on Sat Dec 16 19:49:43 UTC 2023
|
PRIMARY | |||
|
DTXSID10101010
Created by
admin on Sat Dec 16 19:49:43 UTC 2023 , Edited by admin on Sat Dec 16 19:49:43 UTC 2023
|
PRIMARY | |||
|
286834-81-9
Created by
admin on Sat Dec 16 19:49:43 UTC 2023 , Edited by admin on Sat Dec 16 19:49:43 UTC 2023
|
PRIMARY | |||
|
9837232
Created by
admin on Sat Dec 16 19:49:43 UTC 2023 , Edited by admin on Sat Dec 16 19:49:43 UTC 2023
|
PRIMARY | |||
|
5-APB
Created by
admin on Sat Dec 16 19:49:43 UTC 2023 , Edited by admin on Sat Dec 16 19:49:43 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
|
TARGET -> INHIBITOR |
Ki
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
OFF-TARGET->AGONIST |
Indeed all drugs and drug metabolites that induce heart valvular disease in humans activate 5-HT2B receptors in vivo and in vitro and this activity is thought to be important for the development of fibrotic lesions upon chronic human administration.
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
